not used title
not used title
Large pharmacy chains have found ways to financially benefit from the 340B program with little to no benefit to patients. How? In 2010, a misguided policy change enabled 340B hospitals to contract with an unlimited number of for-profit retail pharmacies without meaningful oversight.
Here are three things to know about 340B contract pharmacies:
1. Not improving access for vulnerable patients. While one might expect to find 340B contract pharmacies located in medically underserved neighborhoods to help vulnerable patients access medicines, that isn’t the case. Studies have found the exponential growth in contract pharmacies from 2011 to 2019 was concentrated in affluent and predominately white communities, and not in areas with high unmet need where expansion could help improve health equity.
2. Dominated by large, publicly traded companies. The majority of 340B contract pharmacy arrangements are with for-profit chain pharmacies. Among the top four retail pharmacy chains (Walmart, CVS, Rite Aid and Walgreens), an incredible 71% of locations held 340B contracts in 2022. Walgreens has previously warned investors that policy changes meant to rein in contract pharmacy abuses would reduce the company's profits. CVS Health has admitted the same.
3. Not addressing affordability challenges. There is no clear evidence that 340B hospitals and their contract pharmacies use 340B profits to help lower costs for patients. Rather, contract pharmacies and hospitals generate profits sometimes by charging vulnerable patients the full non-340B price for their prescriptions. An in-depth analysis of claims for brand medicines distributed at 340B contract pharmacies found the vast majority of patients received “zero or close to zero” discount on the cost of their medicines even though the medicines were purchased through the 340B program at a steep discount.
These for-profit entities and their affiliates have found their way into the 340B program to capture profits that could otherwise have been used to lower drug costs for low-income and vulnerable patients. Congress should put an end to the abuse of this important safety net program and put it back on track for the patients it was meant to assist.
Jocelyn Ulrich
Jocelyn Ulrich, MPH, is Vice President of Policy and Research at the Pharmaceutical Research and Manufacturers of America (PhRMA). At PhRMA, she is responsible for developing legislative and policy analysis and research studies on a range of issues impacting innovative biopharmaceutical companies including intellectual property issues, FDA policy issues, the R&D process, the value of innovation, and other issue areas impacting the environment for innovation. In addition to her experience at PhRMA she has over 15 years of experience in the pharmaceutical industry at Pfizer, Human Genome Sciences, and EMD Serono in roles in clinical research management, investigator-initiated and collaborative research, and global policy and corporate affairs. Jocelyn holds an MPH in global health policy and management from New York University.
Jocelyn Ulrich
Hospitals are hiding information that could lower costs for patients
September 24, 2026
New poll: 2 in 3 voters prefer a candidate committed to lowering health insurance premiums
September 18, 2026
As football season kicks off, hospitals keep scoring on 340B
September 9, 2026
ICYMI: Hospital consolidation is driving up health care costs
August 27, 2026
What AARP isn’t telling seniors about MFN
August 24, 2026
It's time to modernize 340B: The case for a rebate model
August 19, 2026
Policymakers should improve patient access and reject price controls
August 18, 2026
Insurers blame GLP-1s for rising costs. The data tells a different story.
August 14, 2026
The FTC’s PBM enforcement actions gave us a glimpse behind the curtain; it’s time to let the light in.
August 7, 2026
Nearly 1 in 4 patients initially denied access to IRA medicines
August 6, 2026
ICYMI: Fox business hosts call 340B a ‘Rotten System’ and ‘Cash Cow’ for hospitals
July 23, 2026
Message to USAging: Providers are raising concerns about coverage barriers
July 22, 2026
New PBM principles don't change the fundamental challenge: Access to lower-cost medicines
July 10, 2026
340B’s reality: A booming business for hospitals, pharmacies and corporate giants
June 25, 2026
Insurers are blaming medicines for premium hikes in Massachusetts. The state's own data suggests otherwise.
June 24, 2026
340B’s lack of guardrails lets big hospital systems turn it into an oversight-free revenue stream
June 22, 2026
Private equity's new play? Become a nonprofit to profit off 340B.
June 5, 2026
340B is growing, but it is unclear if Illinois patients benefit
May 27, 2026
Fox Business spotlights hospitals abuse of the 340B program
May 15, 2026
The Wall Street Journal raises new alarms about 340B
May 11, 2026
Hospitals in the hot seat: Congress sharpens focus on 340B, consolidation and rising costs
May 7, 2026
New "Goldmine” ad reveals hospitals hide how they profit from 340B markups
May 6, 2026
A program off track: How 340B drives both hospital consolidation and system gaming
April 27, 2026
Washington Post Editorial Board says 340B has become “corporate welfare”
April 27, 2026
Briefing: Capitol Hill panel on "Healthcare Denial Crisis in America"
April 24, 2026
Survey confirms too many insured Americans face barriers to reliable health care
April 22, 2026
Modernizing 340B using rapid verification: The case for a rebate model
April 20, 2026
70% DENIED: How insurance denials are delaying and preventing care for millions of Americans
April 14, 2026
Hospitals drive nearly 80% of the U.S. health spending gap
March 25, 2026
Congress should look under the hood of 340B, hospitals don't want them to
March 19, 2026
340B hospitals buy low and sell high, a new analysis shows
March 12, 2026
New report from Minnesota: 340B is generating billions for big hospitals
March 9, 2026
340B hospital markup scheme is costing states, taxpayers billions
February 25, 2026
Questions mount over 340B program and increased cost to everyone
February 23, 2026
No hassle, hidden markups or fees: AmericasMedicines.com
February 19, 2026
PhRMA Forum 2026 highlights the importance of fostering the next era of American leadership
February 18, 2026
The Federal Trade Commission (FTC) takes important action to highlight and curb PBM abuses
February 17, 2026
Separating fact from fiction in the medicine supply chain
February 11, 2026
50-state poll says Americans are concerned that hospital markups hurt patients
January 27, 2026
Three things you should know from the insurer CEO congressional hearings
January 26, 2026
New analysis finds 340B hospitals push patients toward costly care to boost profits
January 21, 2026
Can’t get your medicine? Don’t count on your insurer.
January 15, 2026
Data shows tax-exempt hospital profit-seeking behavior, not drug prices, is driving explosive 340B expansion
January 8, 2026
Big, tax-exempt hospitals are charging cancer patients, employers massive medicine markups
January 5, 2026
340B’s billion-dollar boom: Oversight lags as spending soars
December 19, 2025
New study: 340B rebate model pilot won’t hurt cash flow for providers
December 18, 2025
One thing the Senate can agree on: It’s time to fix 340B
November 25, 2025
Stop, collaborate and re-evaluate: ICER’s pricing report
November 14, 2025
California’s landmark PBM crackdown: A wake-up call for reform
November 13, 2025
Middlemen mark up drug prices and keep discounts meant for you
November 10, 2025
The Administration approves manufacturers’ 340B rebate pilot plans
November 6, 2025
Putting patients first: Breaking down barriers to care
October 28, 2025
Direct purchase programs can lower costs for patients
October 20, 2025
340B abuses are fueling higher Medicare costs, new BRG report shows
October 15, 2025
PBMs say they want lower priced medicines, so why don’t they cover them?
October 7, 2025
Historic biopharmaceutical investments: A prescription for America’s future
September 29, 2025
ICYMI: The Wall Street Journal calls 340B reform a “good idea to cut drug costs”
September 23, 2025
340B hospitals use scare tactics to evade accountability
September 16, 2025
Why states struggle to deliver savings: Middlemen and 340B siphon dollars from patients and states
September 15, 2025
CBO: 340B program costs taxpayers, no evidence patients benefit
September 10, 2025
PhRMA stresses importance of 340B Rebate Model Pilot
September 9, 2025
New “Meet Mark” ad exposes how the 340B hospital markup program drives up costs for everyone
September 3, 2025
New study unmasks how big-city hospitals exploit 340B by posing as rural providers
August 21, 2025
PBMs are hiding hurdles to essential care
August 20, 2025
Study: 340B hospitals drive up patient drug costs
August 15, 2025
Curbing 340B abuse and rising costs with the rebate model
August 12, 2025
New study: PBMs and commercial insurers are quietly blocking prescription access
July 30, 2025
North Carolina puts patients first with rebate pass-through law
July 29, 2025
PBMs, not patents, are blocking access to lower-cost medicines
July 23, 2025
The hidden cost of 340B: A multi-billion-dollar burden on taxpayers and Medicaid
July 14, 2025
Latest analysis from Ohio exposes growing abuses of the 340B markup program
July 7, 2025
New report finds rampant abuse of the 340B program
June 20, 2025
Medicare Part D plans initially denied medicines for more than 70% of patients in four chronic disease areas
June 16, 2025
How the 340B hospital markup program could hurt Michigan patients
June 12, 2025
New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines
May 21, 2025
How the 340B hospital markup program and PBMs drive up costs for U.S. patients
May 16, 2025
Foreign first pricing schemes don’t address why Americans pay more
May 15, 2025
The AHIP premium dollar corrected (again)
May 8, 2025
PBMs launch new ad campaign to block reforms
May 5, 2025
When hospitals have free rein to mark up drug prices, who pays the price?
May 1, 2025
When middlemen own it all, patients pay the price
April 10, 2025
3 myths critics get wrong about intellectual property
March 28, 2025
New report finds more abuse of 340B program by hospitals and drug middlemen
March 24, 2025
A closer look at how health care consolidation drives up patient costs, creates barriers to care
March 17, 2025
Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change
March 13, 2025
Congress Keeps PBMs in the Hot Seat
March 6, 2025
340B markup program is a hidden tax, increasing costs for employers, straining state and federal budgets
March 5, 2025
New report sheds light on payment flows in the pharmaceutical supply chain, including the role of 340B and vertical integration
February 13, 2025
Wrapping up the J.P. Morgan Healthcare Conference
January 16, 2025
NYT exposes hospitals, middlemen make millions off a hospital markup program
January 15, 2025
FTC finds PBMs make billions in profit from marking up cancer, other critical generic drugs
January 14, 2025
PhRMA CEOs Tee Up Next Week's Health Care Conference
January 11, 2025
New study: Entities that don’t make medicines get half of what is spent on those medicines
January 7, 2025
A new administration poses new opportunities for patient access
December 17, 2024
New 340B report from Minnesota exposes steep hospital markups on medicines, patient benefits remain unclear
November 27, 2024
Michigan hospitals using federal program to markup cost of medicines, gouging patients
November 27, 2024
340B spending is exploding, forcing prices up for patients, employers and government programs
November 13, 2024
The PBM industry's desperate attempt to stop reform
November 12, 2024
PhRMA launches new ad calling for Congress to make sure savings go to patients, not PBMs
November 11, 2024
ICYMI: Grounding policy reforms in real lived patient experiences is key to improving outcomes
October 31, 2024
New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election
October 30, 2024
Guest Post: My health care vote
October 29, 2024
Insurers continue shifting more costs on to patients
October 28, 2024
Americans speak out on health insurance barriers and need for policy change, according to the latest Patient Experience Survey
October 28, 2024
ICYMI: The powerful companies driving local drugstores out of business
October 25, 2024
PhRMA urges HRSA not to impede new 340B pricing approaches to improve transparency and integrity
October 18, 2024
Hispanic Heritage Month: Fighting for Hispanic patients
October 7, 2024
Illegal abuse of 340B hurts us all
October 3, 2024
PBMs and insurers off the hook: Sen. Sanders’ selective hearing on drug costs
September 24, 2024
Key voter insights two months from Election Day
September 10, 2024
Patient priorities in the 2024 election
September 10, 2024
Voters across all 50 states want state policymakers to focus on health insurance and PBM practices
July 30, 2024
WTAS: Voters voice concerns about PBM abuses, call on policymakers to act
July 19, 2024
PhRMA launches new ad in campaign exposing ways middlemen drive up costs
July 17, 2024
FTC report confirms PBMs profit at the expense of patients
July 10, 2024
New 50-state poll Americans want to hold health insurers and PBMs accountable for high out-of-pocket costs and other practices
July 9, 2024
ICYMI: Hidden markups at mail-order pharmacies increase costs for employers
July 2, 2024
340B sales go up, free or reduced-cost care offered at hospitals goes down
July 1, 2024
ICYMI: What patients care about this election year
June 24, 2024
ICYMI: The Opaque Industry Secretly Inflating Prices for Prescription Drugs
June 21, 2024
ICYMI: Health care policy should be driven by patients, not politics
June 10, 2024
PhRMA Warns Federal Agencies: Consolidation and vertical integration among insurers, PBMs, and hospitals threaten patients
June 5, 2024
The hidden bill patients don’t know they are paying
June 3, 2024
ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes
May 30, 2024
Ongoing federal probes shed light on PBM and insurer practices
May 20, 2024
340B grows and grows, but patients do not see the savings
May 13, 2024
340B grows and grows, but patients do not see the savings
May 13, 2024
WTAS: The consequences of consolidation and vertical integration
May 6, 2024
Insurance data: PBM reform has no material impact on premiums
April 24, 2024
New study finds insurers and PBMs increasing access restrictions in Medicare Part D
April 16, 2024
3 Takeaways from POLITICO’s Health Care Summit
April 3, 2024
PBMs using 340B program to drive profits at patients’ expense
March 28, 2024
Four years later, Maryland board still hasn’t delivered for patients
February 12, 2024
What’s the 340B program like in your state?
February 7, 2024
New year, same exploitation of the 340B program
January 25, 2024
How the 340B program became a PBM giveaway
December 11, 2023
ICYMI: When middlemen get in the way, it’s the patients who lose
December 5, 2023
Get the facts on PCMA’s newest attempt to avoid accountability
December 4, 2023
ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails
November 15, 2023
New report adds to questions about nonprofit status of 340B hospitals
November 7, 2023
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
November 6, 2023
One year to Election Day: Four voter priorities to watch
November 6, 2023
ICYMI: Scott LaGanga and Matt Salo deliver a State of the Industry Report
October 25, 2023
New poll shows strong bipartisan support for PBM reform
October 20, 2023
4 truths about state government price setting
October 10, 2023
ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs
September 28, 2023
New analysis shows PBMs use fees as a profit center
September 18, 2023
It’s PBMs, not patents, blocking competition
September 14, 2023
By the Numbers: 340B continues to climb in profits, dwindle with patient support
September 13, 2023
New PhRMA ad exposes yet another way PBMs get between patients and their medicines
September 5, 2023
New 340B Mega Guidance
August 3, 2023
New report: Hospitals mark up medicine prices 500%
August 2, 2023
read more
August 2, 2023
PhRMA responds to Senate: Today’s 340B program leaves patients behind | PhRMA
July 28, 2023
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
July 26, 2023
Three things to know from the latest Patient Experience Survey
July 20, 2023
New studies add to body of evidence questioning 340B efficacy
July 11, 2023
340B program reaches $100 billion in sales, while patients are left behind
June 14, 2023
ICYMI: PBM exec admits choosing profits over patients
June 2, 2023
Insulin: Key Facts on Access & Affordability
May 10, 2023
4 key facts on medicine prices and spending
May 9, 2023
4 Things to know about PhRMA’s new 50-state poll
May 4, 2023
New PhRMA ad campaign sheds light on PBM abuses
May 1, 2023
Three facts about health care spending
April 25, 2023
AHIP’s latest misinformation campaign & what it’s trying to hide
April 24, 2023
Nonprofit hospitals fall short on community benefit, studies show
April 24, 2023
ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability
April 7, 2023
States can support access to medicine as COVID-19 Public Health Emergency ends
April 5, 2023
Arkansas puts patients first with new share the savings law
April 4, 2023
Key Trends: Patient experience data reveal how insurers and middlemen impose barriers in health care
March 29, 2023
Insurer and PBM tactics are shifting higher costs to patients with chronic and complex conditions
March 2, 2023
Why Congress should prioritize fixing the 340B program
March 2, 2023
Holding pharmacy benefit managers accountable
February 23, 2023
Stopping pharmacy benefit managers from “gaming the system”
February 22, 2023
What they are saying: Nonprofit hospitals are gaming the system at the expense of patients
February 21, 2023
Senate hearing to examine bipartisan reforms to rein in middlemen
February 16, 2023
Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines
January 31, 2023
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
January 19, 2023
340B program continues to drive shift in care to more expensive hospital settings
December 15, 2022
ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress
December 9, 2022
In their own words: Financial barriers exacerbate access challenges for insured Americans
December 8, 2022
The 340B program is interfering with the U.S. biosimilars market and impacting patient costs
November 21, 2022
New data show how insurers and middlemen shift Rx costs onto patients
November 16, 2022
In their own words: Insured Americans struggle to navigate complex coverage
October 26, 2022
Three ways 340B is failing vulnerable patients
October 20, 2022
New comments outline ways to protect patients from health plans and PBMs who profit from patient assistance
October 7, 2022
If patients aren’t benefiting from the 340B program, who is?
October 6, 2022
New data: The 340B program is driving up costs for patients and our health care system
September 15, 2022
Navigating the patient experience: Burdens and barriers standing between patients and their care
September 12, 2022
Word of the Month: 340B covered entity
August 29, 2022
Insulin and reconciliation
August 15, 2022
Patients win as West Virginia implements first-in-nation share the savings policy
July 8, 2022
3 things voters are concerned about when it comes to their health care coverage
July 7, 2022
340B program remains second largest federal drug program, yet little solid evidence of benefits to patient
June 30, 2022
Study after study after study: Contract pharmacy expansion not aligned in communities 340B is meant to serve
June 24, 2022
Patients support state action requiring PBMs and insurers to share savings and cap costs for medicines
June 16, 2022
New poll shows voters sounding the alarm on health insurance companies and PBMs
June 6, 2022